Avanir raising $88M to fund product launch; Clavis garners 19M euros;

 @FierceBiotech: Merck cites "jaw dropping" data on cholesterol blockbuster contender. Story | Follow @FierceBiotech

 @JohnCFierce: Actelion shares red hot after co. merely noted that it is always engaged in routine talks with other companies. Report | Follow @JohnCFierce

> Pharma's Biggest Flops. Report

> Avanir Pharmaceuticals is selling $88 million in shares to help fund the commercial launch Neudexta, newly approved for involuntary emotional outbursts. Story

> Hot on the heels of a substantial licensing pact with Clovis Oncology, Norway's Clavis Pharma has raised 19 million euros from the sale of shares. Clavis release

> Aeterna Zentaris says it presented promising Phase II efficacy and safety data for its compound, AEZS-108, in advanced endometrial cancer. Aeterna release

> Cambridge, MA-based Stromedix has in-licensed a preclinical antibody program from the UCSF laboratory of Dean Sheppard. "Our clinical development strategy uses a proprietary biomarker database to discover the biologically active dose of an anti-fibrotic agent in the context of a small, short-term trial," says CEO Michael Gilman. "We are excited to be able to leverage what we've learned in the STX-100 program to the αvβ5 antibody and to build a pipeline of valuable biologic drugs to treat chronic and acute organ failure." Stromedix release

> DiscoveRx has acquired the KINOMEscan kinse screening services division from San Diego-based Ambit Biosciences. DiscoveRx release

And Finally... The Top 10 Medical Device Companies of 2010. Report

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.